VIMPAT® (lacosamide) Patent Survives IPR Challenge April 25, 2017 The PTAB upheld the validity of Patent RE38,551 E (“the ’551 patent”), which covers VIMPAT® (lacosamide). See PTAB Litigation Blog by Jones Day, LLP: “Pharmaceutical Compound Nonobvious Absent Evidence Suggesting Specific Modification to Prior Art Compound” IPR2016-00204 Share:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to print (Opens in new window)
